Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors.
Geoerger B, Hargrave D, Thomas F, Ndiaye A, Frappaz D, Andreiuolo F, Varlet P, Aerts I, Riccardi R, Jaspan T, Chatelut E, Le Deley MC, Paoletti X, Saint-Rose C, Leblond P, Morland B, Gentet JC, Méresse V, Vassal G; ITCC (Innovative Therapies for Children with Cancer) European Consortium. Geoerger B, et al. Among authors: meresse v. Neuro Oncol. 2011 Jan;13(1):109-18. doi: 10.1093/neuonc/noq141. Epub 2010 Oct 25. Neuro Oncol. 2011. PMID: 20974795 Free PMC article. Clinical Trial.
Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations.
Zimmer L, Barlesi F, Martinez-Garcia M, Dieras V, Schellens JH, Spano JP, Middleton MR, Calvo E, Paz-Ares L, Larkin J, Pacey S, Venturi M, Kraeber-Bodéré F, Tessier JJ, Eberhardt WE, Paques M, Guarin E, Meresse V, Soria JC. Zimmer L, et al. Among authors: meresse v. Clin Cancer Res. 2014 Aug 15;20(16):4251-61. doi: 10.1158/1078-0432.CCR-14-0341. Epub 2014 Jun 19. Clin Cancer Res. 2014. PMID: 24947927 Clinical Trial.
Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial.
Hartmann O, Le Corroller AG, Blaise D, Michon J, Philip I, Norol F, Janvier M, Pico JL, Baranzelli MC, Rubie H, Coze C, Pinna A, Méresse V, Benhamou E. Hartmann O, et al. Among authors: meresse v. Ann Intern Med. 1997 Apr 15;126(8):600-7. doi: 10.7326/0003-4819-126-8-199704150-00002. Ann Intern Med. 1997. PMID: 9103126 Clinical Trial.
First-in-human phase I clinical trial of RG7356, an anti-CD44 humanized antibody, in patients with advanced, CD44-expressing solid tumors.
Menke-van der Houven van Oordt CW, Gomez-Roca C, van Herpen C, Coveler AL, Mahalingam D, Verheul HM, van der Graaf WT, Christen R, Rüttinger D, Weigand S, Cannarile MA, Heil F, Brewster M, Walz AC, Nayak TK, Guarin E, Meresse V, Le Tourneau C. Menke-van der Houven van Oordt CW, et al. Among authors: meresse v. Oncotarget. 2016 Nov 29;7(48):80046-80058. doi: 10.18632/oncotarget.11098. Oncotarget. 2016. PMID: 27507056 Free PMC article. Clinical Trial.
Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients.
Viens P, Chabannon C, Pouillard P, Janvier M, Brugger W, Blay JY, Oberling F, Capdeville R, Newman C, Méresse V, Xu ZX, Platzer E, Van der Auwera P, Maraninchi D. Viens P, et al. Among authors: meresse v. J Clin Oncol. 2002 Jan 1;20(1):24-36. doi: 10.1200/JCO.2002.20.1.24. J Clin Oncol. 2002. PMID: 11773150 Clinical Trial.
21 results